Business
Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Di
About this update from Profusa, Inc.
[{"type":"image","alt":"Profusa, Inc.","displaySize":"","headline":null,"caption":"Profusa, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k9W1GpBMjzASO6xxhWH6Uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEyOA--/https://media.zenfs.com/en/globenewswire.com/8f79cba194228307ca23a2955a9ec150","width":200,"height":71}},"lazy":false},{"type":"text","content":"Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities","length":133,"tagName":"p"},{"type":"text","content":"Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation","length":146,"tagName":"p"},{"type":"text","content":"BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Directors has initiated a Board-led process to evaluate strategic alternatives intended to maximize shareholder value and support the Company’s highest-priority commercial, regulatory and platform-expansion initiatives.","length":442,"tagName":"p"},{"type":"text","content":"The process will evaluate a range of potential opportunities, including asset-level transactions, commercial and strategic partnerships, business combinations and other corporate transactions.","length":192,"tagName":"p"},{"type":"text","content":"Profusa has engaged Tungsten Advisors as its exclusive strategic financial advisor in connection with this process. There can be no assurance that this process will result in any transaction or other strategic outcome. Profusa does not intend to provide updates unless and until the Board of Directors approves a specific action or otherwise determines that disclosure is appropriate or required.","length":396,"tagName":"p"},{"type":"text","content":"Concurrently, Profusa is aligning its resources and capital allocation priorities around initiatives the Company believes can best support near-term execution and value creation, including advancing European CE Mark approval through GMED under the EU Medical Device Regulat...